Tenofovir: 4 agencies, 2006–2022
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
PHARMAC (New Zealand) has been easier on tenofovir than on its own caseload: it refused 0 of 8 decisive submissions here (0%), against a base rate of 29% across everything it has assessed.
The file has been open for more than a decade: 15.9 years separate the first record, 1 Aug 2006 at PHARMAC (New Zealand), from the most recent, 2022 at PBAC (Australia).
PBAC (Australia) changed its position: not recommended in 2016, recommended by 2021, after a resubmission.
Coverage is thin among the largest agencies: 5 of the eight highest-volume bodies — HAS (France), AWMSG (Wales) and TLV (Sweden) among them — hold no record for tenofovir at all.
The programme is broad: 8 distinct indication wordings are recorded for tenofovir by the agencies that label one in English (PBAC and SMC).
13 of these 23 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
PHARMAC (New Zealand) was first to assess tenofovir, on 1 Aug 2006; CONITEC (Brazil) did not open a file until 7 Dec 2016 — an unusually long tail of 10.3 years between the earliest and latest system to look at it.
The record arrives in waves: 6 separate years each carry two or more decisions, spread across 10 years in total.
2 of the 4 agencies here assessed tenofovir more than once, PBAC (Australia) most often at 13 entries — repeat review is the norm for this molecule rather than the exception.
Coverage is narrow: only 4 of the 18 agencies here have assessed tenofovir.
The full ledger for tenofovir reads 17 recommended, 3 deferred, 2 other and 1 not recommended.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| PBAC (Australia) | 2022 | Hepatitis B | The PBAC advised that the March 2017 recommendation could be revoked, noting that the reco… | source |
| PHARMAC (New Zealand) | 9 Feb 2017 | Hepatitis B - women of childbearing potential | PTAC advice: High · decision reached | source |
| CONITEC (Brazil) | 7 Dec 2016 | Tratamento da hepatite crônica viral B sem agente delta, compatibilizando o código B18.1 da CID10 com os respectivos pro… | incorporated into SUS | source |
| PHARMAC (New Zealand) | 14 Feb 2013 | Hepatitis B, with decompensated cirrhosis | PTAC advice: High · decision reached | source |
| SMC (Scotland) | 7 Jul 2008 | chronic hepatitis B (CHB) in adults with compensated liver disease with evidence of active viral replication, persistently (i.e. at least 6 months) elevated serum alanine… | accepted | source |
18 further decisions for tenofovir, across 2 agencies, are not shown here. They link to 6 further source documents.
Related molecules
- raltegravir — divergent outcome (recommended vs restricted) on a shared indication
- bictegravir / emtricitabine / tenofovir alafenamide — divergent outcome (recommended vs restricted) on a shared indication
- sofosbuvir — same ATC class J05A — Antivirals
- letermovir — same ATC class J05A — Antivirals
- cabotegravir — same ATC class J05A — Antivirals
- darunavir — same ATC class J05A — Antivirals
Coverage: 23 decisions for tenofovir from 4 agencies, 2006 to 2022. Data to 7 Sep 2026. ATC class J05A — Antivirals. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.